1
|
Raviola S, Griffante G, Iannucci A, Chandel S, Lo Cigno I, Lacarbonara D, Caneparo V, Pasquero S, Favero F, Corà D, Trisolini E, Boldorini R, Cantaluppi V, Landolfo S, Gariglio M, De Andrea M. Human cytomegalovirus infection triggers a paracrine senescence loop in renal epithelial cells. Commun Biol 2024; 7:292. [PMID: 38459109 PMCID: PMC10924099 DOI: 10.1038/s42003-024-05957-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Accepted: 02/22/2024] [Indexed: 03/10/2024] Open
Abstract
Human cytomegalovirus (HCMV) is an opportunistic pathogen causing severe diseases in immunosuppressed individuals. To replicate its double-stranded DNA genome, HCMV induces profound changes in cellular homeostasis that may resemble senescence. However, it remains to be determined whether HCMV-induced senescence contributes to organ-specific pathogenesis. Here, we show a direct cytopathic effect of HCMV on primary renal proximal tubular epithelial cells (RPTECs), a natural setting of HCMV disease. We find that RPTECs are fully permissive for HCMV replication, which endows them with an inflammatory gene signature resembling the senescence-associated secretory phenotype (SASP), as confirmed by the presence of the recently established SenMayo gene set, which is not observed in retina-derived epithelial (ARPE-19) cells. Although HCMV-induced senescence is not cell-type specific, as it can be observed in both RPTECs and human fibroblasts (HFFs), only infected RPTECs show downregulation of LAMINB1 and KI67 mRNAs, and enhanced secretion of IL-6 and IL-8, which are well-established hallmarks of senescence. Finally, HCMV-infected RPTECs have the ability to trigger a senescence/inflammatory loop in an IL-6-dependent manner, leading to the development of a similar senescence/inflammatory phenotype in neighboring uninfected cells. Overall, our findings raise the intriguing possibility that this unique inflammatory loop contributes to HCMV-related pathogenesis in the kidney.
Collapse
Affiliation(s)
- Stefano Raviola
- Intrinsic Immunity Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Gloria Griffante
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Andrea Iannucci
- Intrinsic Immunity Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - Shikha Chandel
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Irene Lo Cigno
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Davide Lacarbonara
- Intrinsic Immunity Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Valeria Caneparo
- Intrinsic Immunity Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
| | - Selina Pasquero
- Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, University of Turin, Medical School, Turin, Italy
| | - Francesco Favero
- Bioinformatics Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
- Bioinformatics Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Davide Corà
- Bioinformatics Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
- Bioinformatics Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Elena Trisolini
- Pathology Unit, Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | - Renzo Boldorini
- Pathology Unit, Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | - Vincenzo Cantaluppi
- Nephrology and Kidney Transplantation Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Santo Landolfo
- Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, University of Turin, Medical School, Turin, Italy
| | - Marisa Gariglio
- Intrinsic Immunity Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy
- Molecular Virology Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Marco De Andrea
- Intrinsic Immunity Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Eastern Piedmont, Novara, Italy.
- Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, University of Turin, Medical School, Turin, Italy.
| |
Collapse
|
2
|
Mastromarino MG, Parini S, Azzolina D, Habib S, De Marni ML, Luise C, Restelli S, Baietto G, Trisolini E, Massera F, Papalia E, Bora G, Carbone R, Casadio C, Boldorini R, Rena O. Liquid Biopsy Detecting Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer: Preliminary Results of a Pilot Study. Biomedicines 2023; 11:biomedicines11010153. [PMID: 36672660 PMCID: PMC9855397 DOI: 10.3390/biomedicines11010153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 12/29/2022] [Accepted: 01/04/2023] [Indexed: 01/11/2023] Open
Abstract
Lung cancer is still the leading cause of cancer-related death worldwide. Interest is growing towards early detection and advances in liquid biopsy to isolate circulating tumor cells (CTCs). This pilot study aimed to detect epithelial CTCs in the peripheral blood of early-stage non-small cell lung cancer (NSCLC) patients. We used Smart BioSurface® (SBS) slide, a nanoparticle-coated slide able to immobilize viable nucleated cellular fraction without pre-selection and preserve cell integrity. Forty patients undergoing lung resection for NSCLC were included; they were divided into two groups according to CTC value, with a cut-off of three CTCs/mL. All patients were positive for CTCs. The mean CTC value was 4.7(± 5.8 S.D.) per ml/blood. In one patient, next generation sequencing (NGS) analysis of CTCs revealed v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation, which has also been identified in tissue biopsy. CTCs count affected neither overall survival (OS, p = 0.74) nor progression-free survival (p = 0.829). Multivariable analysis confirmed age (p = 0.020) and pNodal-stage (p = 0.028) as negative predictors of OS. Preliminary results of this pilot study suggest the capability of this method in detecting CTCs in all early-stage NSCLC patients. NGS on single cell, identified as CTC by immunofluorescence staining, is a powerful tool for investigating the molecular landscape of cancer, with the aim of personalized therapies.
Collapse
Affiliation(s)
- Maria Giovanna Mastromarino
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
- Correspondence: ; Tel.: +39-0321/3732111
| | - Sara Parini
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | - Danila Azzolina
- Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy
| | - Sara Habib
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | | | | | | | - Guido Baietto
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | - Elena Trisolini
- Division of Pathology, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | - Fabio Massera
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | - Esther Papalia
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | - Giulia Bora
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | | | - Caterina Casadio
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
| | - Renzo Boldorini
- Division of Pathology, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
- Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Ottavio Rena
- Division of Thoracic Surgery, Ospedale Maggiore della Carità di Novara, 28100 Novara, Italy
- Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| |
Collapse
|
3
|
Ebrahimi A, Korshunov A, Reifenberger G, Capper D, Felsberg J, Trisolini E, Pollo B, Calatozzolo C, Prinz M, Staszewski O, Schweizer L, Schittenhelm J, Harter PN, Paulus W, Thomas C, Kohlhof-Meinecke P, Seiz-Rosenhagen M, Milde T, Casalini BM, Suwala A, Wefers AK, Reinhardt A, Sievers P, Kramm CM, Etminam N, Unterberg A, Wick W, Herold-Mende C, Sturm D, Pfister SM, Sill M, Jones DTW, Schrimpf D, Reuss DE, Aldape K, Abdullaev Z, Sahm F, von Deimling A, Stichel D. Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathol Commun 2022; 10:5. [PMID: 35012690 PMCID: PMC8751269 DOI: 10.1186/s40478-021-01308-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Accepted: 12/24/2021] [Indexed: 11/18/2022] Open
Abstract
Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA.
Collapse
|
4
|
Rrapaj E, Giacometti L, Spina P, Salvo M, Baselli GA, Veggiani C, Rena O, Trisolini E, Boldorini RL. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. Pathology 2020; 53:462-469. [PMID: 33272690 DOI: 10.1016/j.pathol.2020.09.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 08/30/2020] [Accepted: 09/04/2020] [Indexed: 01/22/2023]
Abstract
Malignant pleural mesothelioma (MPM) is often associated with a poor prognosis and options for the treatment of this disease are few. To date, the important role of the immune microenvironment in modifying the disease natural history is well established. The programmed cell death pathway (PD-1/PD-L1) limits the T lymphocyte activation in peripheral tissues when an inflammatory response occurs, and controls the tumour immune escape. PD-L1 is broadly expressed in several malignant tumours and associated with poor clinical outcomes. Thus, the aim of our study is to investigate the potential role of PD-L1 expression in MPM prognosis. Biopsy samples from 198 patients diagnosed with MPM were examined by immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR) to evaluate PD-L1 protein and gene expression. For PD-L1 protein expression we consider at least 5% membranous staining as positive. Gene expression levels were calculated with ΔΔCt method. Positive expression of PD-L1 by IHC was correlated with worse overall survival (OS; p=0.0225) in MPM patients. PD-L1 positive status was correlated with worse OS in the subgroup of patients with ECOG score <2 (p=0.0004, n=129) and these data were confirmed by multivariate analysis. No significant correlation was found between PD-L1 gene expression and OS. Our results show that PD-L1 evaluated by IHC assay may be a prognostic biomarker for MPM patients with good performance status.
Collapse
Affiliation(s)
- Eltjona Rrapaj
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.
| | - Lorenzo Giacometti
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | - Paolo Spina
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy; Cantonal Institute of Pathology, Locarno, Switzerland
| | - Michela Salvo
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy; Unit of Pathology, Maggiore Della Carita Hospital, Novara, Italy
| | - Guido Alessandro Baselli
- Translational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - Claudia Veggiani
- Unit of Pathology, Maggiore Della Carita Hospital, Novara, Italy
| | - Ottavio Rena
- Unit of Thoracic Surgery, Maggiore Della Carita Hospital, Novara, Italy
| | - Elena Trisolini
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy; Unit of Pathology, Maggiore Della Carita Hospital, Novara, Italy
| | - Renzo Luciano Boldorini
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy; Unit of Pathology, Maggiore Della Carita Hospital, Novara, Italy
| |
Collapse
|
5
|
Armellini E, Manfrin E, Trisolini E, Andorno S, Ballarè M, Bernardoni L, Boldorini RL, Gabbrielli A, Frulloni L, Larghi A, Occhipinti P, Scarpa A, Crinò SF. Histologic retrieval rate of a newly designed side-bevelled 20G needle for EUS-guided tissue acquisition of solid pancreatic lesions. United European Gastroenterol J 2018; 7:96-104. [PMID: 30788121 DOI: 10.1177/2050640618804443] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 08/27/2018] [Indexed: 12/14/2022] Open
Abstract
Background Innovative approaches to improve diagnostic yield of endoscopic ultrasound-guided tissue acquisition (EUS-TA) have focused on needle design with development of fine-needle biopsy (FNB) needles with microcore-acquisition technology. Recently, a 20-gauge (20G) antegrade-cutting-side-bevelled biopsy needle (ProCore®) was developed for EUS-TA, but data about its diagnostic performance and histological capability are scant. Objectives We assessed the diagnostic performance and histologic retrieval rate of a new 20G antegrade-cutting-side-bevelled biopsy needle compared with a 22G reverse-side-bevelled needle for EUS sampling of solid pancreatic lesions. Patients and methods A retrospective analysis of 238 consecutively collected patients who underwent EUS-TA using a 20G or a 22G ProCore® needle, without rapid on-site evaluation (ROSE), was conducted at two centres.Sensitivity, specificity, positive predictive value and negative predictive value were calculated. Histologic tissue retrieval was evaluated applying a scoring system for each case. Results Sensitivity and specificity were estimated as 98.4-100% in the 20G-, and 94.9-100% in the 22G-needle groups, respectively (p > 0.99). The 20G procured more histologic-grade tissues (92.6% vs 49.5%, p < 0.0001) achieved by a lower number of passes (2.64 vs 3.44, p < 0.0001) compared to the 22G. Conclusions Both side-bevelled FNB needles achieved a high diagnostic sensitivity. The 20G-side-bevelled needle obtained a significantly higher microcore retrieval rate.
Collapse
Affiliation(s)
- Elia Armellini
- Department of Gastroenterology, 'Maggiore della Carità' Hospital, Novara, Italy
| | - Erminia Manfrin
- Department of Pathology and Diagnostics, G.B. Rossi University Hospital, Verona, Italy
| | - Elena Trisolini
- Department of Health Sciences, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Silvano Andorno
- Department of Health Sciences, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Marco Ballarè
- Department of Gastroenterology, 'Maggiore della Carità' Hospital, Novara, Italy
| | - Laura Bernardoni
- Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy
| | - Renzo Luciano Boldorini
- Department of Health Sciences, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy.,Department of Pathology, 'Maggiore della Carità' Hospital, Novara, Italy
| | - Armando Gabbrielli
- Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy
| | - Luca Frulloni
- Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy
| | - Alberto Larghi
- Digestive Endoscopy Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| | - Pietro Occhipinti
- Department of Gastroenterology, 'Maggiore della Carità' Hospital, Novara, Italy
| | - Aldo Scarpa
- Department of Pathology and Diagnostics, G.B. Rossi University Hospital, Verona, Italy.,ARC-Net Research Centre, G.B. Rossi University Hospital, Verona, Italy
| | - Stefano Francesco Crinò
- Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy
| |
Collapse
|
6
|
Di Stefano AL, Picca A, Saragoussi E, Berzero G, Alentorn A, Touat M, Ducray F, Villa C, Trisolini E, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Lasorella A, Iavarone A, Mokhtari K, Savatovsky J, Bielle F, Sanson M. Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Alberto Picca
- Neuroscience Consortium, University of Pavia, Monza Policlinico and Pavia Mondino, Pavia, Italy
| | - Edouard Saragoussi
- Departments of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Giulia Berzero
- Neuroscience Consortium, University of Pavia, Monza Policlinico and Pavia Mondino, Pavia, Italy
| | | | - Mehdi Touat
- Hôpital Pitié Salpétrière, Villejuif, France
| | - Francois Ducray
- Service de Neuro-oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France
| | - Chiara Villa
- Department of Pathology, Foch Hospital, Suresnes, France
| | - Elena Trisolini
- Department of Health Science, University of Eastern Piedmont “Amedeo Avogadro”, Novara, Italy
| | - Yohann Schmitt
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
| | - Ahmed Idbaih
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
| | - Khe Hoang-Xuan
- AP-HP, Hôpital La Pitié Salpêtrière, IGCNO, Paris, France
| | - Jean-Yves Delattre
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
| | - Anna Lasorella
- Institute for Cancer Genetics, Columbia University, New York, NY
| | - Antonio Iavarone
- Institute for Cancer Genetics, Columbia University,, New York, NY
| | | | - Julien Savatovsky
- Service d'imagerie Médicale Fondation Ophtalmologique A de Rothschild, Paris, France
| | | | - Marc Sanson
- Universite Pierre Et Marie Curie-Paris 6, Centre de Recherche de L'institut Du Cerveau et de la Moelle Épinière (CRICM), Neurologie 2, Paris, France
| |
Collapse
|
7
|
Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 2018; 90:e2086-e2094. [PMID: 29728520 DOI: 10.1212/wnl.0000000000005658] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2017] [Accepted: 03/19/2018] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVE To characterize the prevalence and prognostic significance of major driver molecular alterations in adult midline diffuse gliomas (MLG). METHODS Adults with histologically proven MLG diagnosed between 1996 and 2017 were identified from our tumor bank, systematically reviewed, and reclassified according to WHO 2016. Targeted sequencing was performed, including determination of H3F3A, HIST1H3B, TERTp, IDH1/2, FGFR1, p16/CDKN2A, and EGFR status. RESULTS A total of 116 adult patients (M/F 71/45, median age 46.5 years) with MLG (17 cerebellar, 8 spinal, 30 brainstem, 57 thalamic, and 4 diencephalic nonthalamic) were identified. Most patients had high-grade disease at presentation (grade II: 11%, grade III: 15%, grade IV: 75%). Median overall survival was 17.3 months (14.5-23.8 months). Main molecular alterations observed were TERT promoter, H3F3A, and hotspot FGFR1 (N546 and K656) mutations, in 37%, 34%, and 18% of patients, respectively. IDH1 mutations only affected brainstem gliomas (6/24 vs 0/78; p = 7.5 × 10-5), were mostly non-R132H (contrasting with hemispheric gliomas, p = 0.0001), and were associated with longer survival (54 vs 12 months). TERT promoter mutation (9.1 vs 24.2 months), CDKN2A deletion (9.9 vs 23.8 months), and EGFR amplification (4.3 vs 23.8 months) were associated with shorter survival. Of interest, in contrast with pediatric MLG, H3K27M mutations were not associated with worse prognosis (23 vs 15 months). CONCLUSIONS Patients with adult MLG present with unique clinical and molecular characteristics, differing from their pediatric counterparts. The identification of potentially actionable FGFR1 mutations in a subset of adult MLG highlights the importance of comprehensive genomic analysis in this rare affection.
Collapse
Affiliation(s)
- Alberto Picca
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Giulia Berzero
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Franck Bielle
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Mehdi Touat
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Julien Savatovsky
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Marc Polivka
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Elena Trisolini
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Sheida Meunier
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Yohann Schmitt
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Ahmed Idbaih
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Khe Hoang-Xuan
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Jean-Yves Delattre
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Karima Mokhtari
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Anna Luisa Di Stefano
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France
| | - Marc Sanson
- From Sorbonne Université (A.P., G.B., F.B., M.T., E.T., S.M., Y.S., A.I., K.H.-X., J.-Y.D., K.M., A.L.D.S., M.S.), UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM; Service de Neurologie 2 (A.P., G.B., M.T., A.I., K.H.-X., J.-Y.D., M.S.) and Laboratoire R Escourolle 2 (F.B., K.M.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Neuroscience Consortium (A.P., G.B.), Monza Policlinico and Pavia Mondino, University of Pavia, Italy; Centre d'Imagerie (J.S.), Fondation A de Rothschild; Laboratoire d'Anatomie Pathologique (M.P.), AP-HP, Hôpital Lariboisière, Paris, France; Pathology Unit (E.T.), AOU "Maggiore della Carità" di Novara, Italy; Onconeurotek Tumour Bank (J.-Y.D., K.M., M.S.), GH Pitié-Salpêtrière; and Department of Neurology (A.L.D.S.), Foch Hospital, Suresnes, Paris, France.
| |
Collapse
|
8
|
Rrapaj E, Trisolini E, Bertero L, Salvo M, Indellicato R, Andorno S, Garcia-Manteiga JM, Rena O, Boldorini RL. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma. Histopathology 2018; 72:1039-1050. [PMID: 29356044 DOI: 10.1111/his.13470] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Accepted: 01/17/2018] [Indexed: 01/12/2023]
Abstract
AIMS High mobility group box 1 (HMGB1) is a chromatin structural protein, expressed ubiquitously in the nuclei of mammalian cells. When transported extracellularly, it acts as a tumour suppressor and oncogenic protein. In malignant pleural mesothelioma (MPM), high serum levels of HMGB1 have been related to a poor prognosis. Conversely, the significance of HMGB1 expression in MPM tissues is still unclear. METHODS AND RESULTS Biopsy samples from 170 patients with MPM were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) to evaluate HMGB1 protein and gene expression. The expression level of HMGB1 protein was scored using a semiquantitative system that sums the intensity (0-3) and the percentage (from 0 to 4) of positively stained cells in nuclei, cytoplasm and in both. The final score was considered as high (>3) or low (<3) expression. Gene expression levels were calculated using the ΔΔCt method. High expression levels of HMGB1 as total (P = 0.0011) and cytoplasmic score (P = 0.0462) were related to a worse disease-specific survival (DSS) in the entire cohort and in the clinicopathological subgroups. No significant correlation was found between HMGB1 gene expression and DSS. CONCLUSIONS These findings indicate that HMGB1 may be a useful prognostic biomarker in MPM when detected by immunohistochemistry. Conversely, as it is also expressed in normal and reactive mesothelial cells, HMGB1 cannot be considered a diagnostic biomarker in histological samples of mesothelioma.
Collapse
Affiliation(s)
- Eltjona Rrapaj
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | - Elena Trisolini
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | - Luca Bertero
- Division of Pathology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Michela Salvo
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | | | - Silvano Andorno
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
| | - Jose M Garcia-Manteiga
- Center For Translational Genomics and Bioinformatics, IRCCS San Raffaele Hospital, Milan, Italy
| | - Ottavio Rena
- Unit of Thoracic Surgery, Maggiore della Carità Hospital, Novara, Italy
| | - Renzo L Boldorini
- Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.,Unit of Pathology, Maggiore della Carità Hospital, Novara, Italy
| |
Collapse
|
9
|
Borgogna C, Olivero C, Lanfredini S, Calati F, De Andrea M, Zavattaro E, Savoia P, Trisolini E, Boldorini R, Patel GK, Gariglio M. β-HPV Infection Correlates with Early Stages of Carcinogenesis in Skin Tumors and Patient-Derived Xenografts from a Kidney Transplant Recipient Cohort. Front Microbiol 2018; 9:117. [PMID: 29459852 PMCID: PMC5807414 DOI: 10.3389/fmicb.2018.00117] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Accepted: 01/18/2018] [Indexed: 11/15/2022] Open
Abstract
Many malignancies that occur in high excess in kidney transplant recipients (KTRs) are due to viruses that thrive in the setting of immunosuppression. Keratinocyte carcinoma (KC), the most frequently occurring cancer type in KTR, has been associated with skin infection by human papillomavirus (HPV) from the beta genus. In this report, we extend our previous investigation aimed at identifying the presence of active β-HPV infection in skin tumors from KTRs through detection of viral protein expression. Using a combination of antibodies raised against the E4 and L1 proteins of the β-genotypes, we were able to visualize infection in five tumors [one keratoacanthoma (KA), three actinic keratoses (AKs), and one seborrheic keratoses (SKs)] that were all removed from two patients who had been both transplanted twice, had developed multiple KCs, and presented with a long history of immunosuppression (>30 years). These infected tissues displayed intraepidermal hyperplasia and increased expression of the ΔNp63 protein, which extended into the upper epithelial layers. In addition, using a xenograft model system in nude mice displaying a humanized stromal bed in the site of grafting, we successfully engrafted three AKs, two of which were derived from the aforementioned KTRs and displayed β-HPV infection in the original tumor. Of note, one AK-derived xenograft, along with its ensuing lymph node metastasis, was diagnosed as squamous cell carcinoma (SCC). In the latter, both β-HPV infection and ΔNp63 expression were no longer detectable. Although the overall success rate of engrafting was very low, the results of this study show for the first time that β-HPV+ and ΔNp63+ intraepidermal hyperplasia can indeed progress to an aggressive SCC able to metastasize. Consistent with a series of reports attributing a causative role of β-HPV at early stages of skin carcinogenesis through ΔNp63 induction and increased keratinocytes stemness, here we provide in vivo evidence that these events are also occurring in the affected skin of KTRs. Due to these β-HPV-driven molecular pathways, the nascent tumor cell is able to acquire a high enough number of carcinogenic insults that its proliferation and survival will eventually become independent of viral gene expression.
Collapse
Affiliation(s)
- Cinzia Borgogna
- Virology Unit, Department of Translational Medicine, Novara Medical School, University of Eastern Piedmont, Novara, Italy
| | - Carlotta Olivero
- Virology Unit, Department of Translational Medicine, Novara Medical School, University of Eastern Piedmont, Novara, Italy.,School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom
| | - Simone Lanfredini
- School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom
| | - Federica Calati
- Virology Unit, Department of Translational Medicine, Novara Medical School, University of Eastern Piedmont, Novara, Italy
| | - Marco De Andrea
- Virology Unit, Department of Translational Medicine, Novara Medical School, University of Eastern Piedmont, Novara, Italy.,Virology Unit, Department of Public Health and Pediatric Sciences, Turin Medical School, University of Turin, Turin, Italy
| | - Elisa Zavattaro
- Dermatology Unit, Department of Health Sciences, Novara Medical School, Novara, Italy
| | - Paola Savoia
- Dermatology Unit, Department of Health Sciences, Novara Medical School, Novara, Italy
| | - Elena Trisolini
- Pathology Unit, Department of Health Sciences, Novara Medical School, Novara, Italy
| | - Renzo Boldorini
- Pathology Unit, Department of Health Sciences, Novara Medical School, Novara, Italy
| | - Girish K Patel
- School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom
| | - Marisa Gariglio
- Virology Unit, Department of Translational Medicine, Novara Medical School, University of Eastern Piedmont, Novara, Italy
| |
Collapse
|
10
|
Imarisio C, Alchera E, Bangalore Revanna C, Valente G, Follenzi A, Trisolini E, Boldorini R, Carini R. Oxidative and ER stress-dependent ASK1 activation in steatotic hepatocytes and Kupffer cells sensitizes mice fatty liver to ischemia/reperfusion injury. Free Radic Biol Med 2017; 112:141-148. [PMID: 28739531 DOI: 10.1016/j.freeradbiomed.2017.07.020] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 07/17/2017] [Accepted: 07/21/2017] [Indexed: 12/12/2022]
Abstract
UNLABELLED Steatosis intensifies hepatic ischemia/reperfusion (I/R) injury increasing hepatocyte damage and hepatic inflammation. This study evaluates if this process is associated to a differential response of steatotic hepatocytes (HP) and Kupffer cells (KC) to I/R injury and investigates the molecular mechanisms involved. Control or steatotic (treated with 50 μmol palmitic acid, PA) mouse HP or KC were exposed to hypoxia/reoxygenation (H/R). C57BL/6 mice fed 9 week with control or High Fat diet underwent to partial hepatic IR. PA increased H/R damage of HP and further activated the ASK1-JNK axis stimulated by ER stress during H/R. PA also induced the production of oxidant species (OS), and OS prevention nullified the capacity of PA to increase H/R damage and ASK1/JNK stimulation. ASK1 inhibition prevented JNK activation and entirely protected HP damage. In KC, PA directly activated ER stress, ASK1 and p38 MAPK and increased H/R damage. However, in contrast to HP, ASK1 inhibition further increased H/R damage by preventing p38 MAPK activation. In mice liver, steatosis induced the expression of activated ASK1 in only KC, whereas I/R exposure of steatotic liver activated ASK1 expression also in HP. "In vivo", ASK1 inhibition prevented ASK1, JNK and p38 MAPK activation and protected I/R damage and expression of inflammatory markers. CONCLUSIONS Lipids-induced ASK1 stimulation differentially affects HP and KC by promoting cytotoxic or protective signals. ASK1 increases H/R damage of HP by stimulating JNK and protects KC activating p38MAPK. These data support the potentiality of the therapeutic employment of ASK1 inhibitors that can antagonize the damaging effects of I/R upon fatty liver surgery by the contextual reduction of HP death and of KC-mediated reactions.
Collapse
Affiliation(s)
- Chiara Imarisio
- Department of Health Science, University of Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy.
| | - Elisa Alchera
- Department of Health Science, University of Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy.
| | | | - Guido Valente
- Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
| | - Antonia Follenzi
- Department of Health Science, University of Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy.
| | - Elena Trisolini
- Department of Health Science, University of Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy.
| | - Renzo Boldorini
- Department of Health Science, University of Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy.
| | - Rita Carini
- Department of Health Science, University of Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy.
| |
Collapse
|
11
|
Mancuso G, Antona J, Sirini C, Salvo M, Giacometti L, Olivero C, Trisolini E, Indellicato R, Boldorini R. Frequent detection of Merkel cell polyomavirus DNA in tissues from 10 consecutive autopsies. J Gen Virol 2017; 98:1372-1376. [PMID: 28613147 DOI: 10.1099/jgv.0.000778] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Merkel cell polyomavirus (MCPyV) has been identified in samples of Merkel cell carcinoma (MCC), an aggressive skin cancer. Seroepidemiologic studies indicated a high frequency of MCPyV infection in humans, suggesting respiratory and faecal-oral routes, or transmission by skin contact. Since MCC is more frequent in immunocompromised patients, a reactivation of MCPyV latently infecting target cells has been proposed. However, neither definite ways of transmission nor specific target organs have been identified with certainty. Ten autopsies with an extensive organ sampling for a total of 121 specimens (tissue and blood samples) were collected. All tissue specimens were fixed in formalin and embedded in paraffin. Real-time PCR was performed to quantify the copy number of the large T antigen (LT) gene and the capsid VP1 gene of MCPyV. MCPyV LT and/or VP genes were detected in all of the collected specimens. A high prevalence of MCPyV was found in the blood (six cases) and lung (five cases); the brain was positive in three cases. The highest viral copy number was detected in blood from two autopsies (21 610 570.09 copies per 105 cells and 380 413.25 copies per 105 cells), whereas the viral copy number in the other organs was low. Our data confirm the high frequency of MCPyV infection in the general population, which seems to indicate that the respiratory tract is a possible route for viral transmission and viral persistence in the brain. The frequent detection of MCPyV DNA in blood suggests that circulating leukocytes could be one of the reservoirs of MCPyV, whereas the high viral copy number also seems to indicate the possibility of viral reactivation in immunocompetent adults.
Collapse
Affiliation(s)
- Giuseppe Mancuso
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Jlenia Antona
- Department of Pathology, Maggiore della Carità Hospital, Novara, Italy
| | - Camilla Sirini
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Michela Salvo
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Lorenzo Giacometti
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Carlotta Olivero
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Elena Trisolini
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Rossella Indellicato
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Renzo Boldorini
- Department of Pathology, Maggiore della Carità Hospital, Novara, Italy
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| |
Collapse
|
12
|
Trisolini E, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M, Pizio C, Mancuso G, Andorno S, Boldorini R. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. Pathology 2017; 49:379-386. [PMID: 28450086 DOI: 10.1016/j.pathol.2016.12.348] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 12/09/2016] [Accepted: 12/20/2016] [Indexed: 02/09/2023]
Abstract
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the procedure of choice for the cytologic diagnosis of pancreatic masses. The specificity of EUS-FNA approaches 100%, but the sensitivity is still low, and the high rate of indeterminate (atypical and suspicious) and false-negative results needs improvement. KRAS gene is frequently mutated in pancreatic ductal adenocarcinoma (PDAC) (up to 90%), and mutation analysis of KRAS has been proposed as diagnostic biomarker of PDAC. In most laboratories, KRAS mutation testing is performed by Sanger sequencing or real time-quantitative polymerase chain reaction (RT-qPCR), but these methods may give false-negative results in routine samples, mainly due to low cellularity. In order to increase the sensitivity of EUS-FNA, we propose a sequential approach for detecting KRAS mutations using mutant enriched-PCR (ME-PCR, sensitivity up to 0.1%) in cytologically indeterminate and negative samples tested wild-type by RT-qPCR. EUS-FNA specimens from 107 patients with pancreatic masses (51 males, 56 females, mean age 67 years) were cytologically examined. According to the Papanicolaou Society of Cytopathology guidelines, 50 cases (47%) were classified malignant, 15 (14%) suspicious, 13 (12%) atypical and 10 (9%) negative for malignancy; 18 cases (17%) were non-diagnostic. The overall specificity and sensitivity of cytological examination were 100% and 61%, respectively, when only negative and positive cases were considered; when atypical and suspicious were added to positive cases, the sensitivity increased to 95.1% and the specificity decreased to 85.7%. In all the cases, DNA was extracted from the cell-block and KRAS mutations were investigated by RT-qPCR, followed by ME-PCR in non-amplifiable and negative cases. The overall sensitivity and specificity of KRAS mutation testing alone were 79.3% and 100%; when KRAS mutation testing was performed in indeterminate and negative cytology, the sensitivity increased to 90% with specificity to 100%. Our data indicate that conventional cytology from EUS-FNA samples is highly specific for the diagnosis of pancreatic cancer. Indeterminate and negative cases need to be screened for KRAS mutations; this two-step approach may greatly improve the diagnostic accuracy of this method.
Collapse
Affiliation(s)
- Elena Trisolini
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Elia Armellini
- Unit of Gastroenterology, 'Maggiore della Carità' Hospital, Novara, Italy
| | | | - Claudia Veggiani
- Unit of Pathology, 'Maggiore della Carità' Hospital, Novara, Italy
| | - Cristina Bozzola
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | | | - Corinna Pizio
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Giuseppe Mancuso
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Silvano Andorno
- Unit of Medical Statistics and Cancer Epidemiology, Department of Translational Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy
| | - Renzo Boldorini
- Department of Health Science, School of Medicine, University of Eastern Piedmont 'Amedeo Avogadro', Novara, Italy; Unit of Pathology, 'Maggiore della Carità' Hospital, Novara, Italy.
| |
Collapse
|
13
|
Bertero L, Mancuso G, Callipo F, Traballi L, Cassoni P, Senetta R, Rudà R, Antona J, Trisolini E, Boldorini R. P03.01 Expression analysis and prognostic/predictive significance of a panel of microRNAs (miR-124a, miR-381, miR-637) in primary IDH-wildtype glioblastoma. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Marchio C, Trisolini E, Maletta F, Annaratone L, Scalzo MS, Mascali D, Verdun di Cantogno L, Medico E, Sapino A. Abstract P6-05-04: Stratification of breast carcinomas with double-equivocal HER2 status. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND AND RATIONALE: Immunohistochemistry (IHC) and in situ hybridization (ISH) represent the cornerstone of HER2 evaluation in breast cancer (BC). We have demonstrated that up to 13% of BCs with equivocal HER2 expression (score 2+ in IHC) harbor an equivocal HER2 gene status (HER2/CEP17 <2 and mean HER2 copy number between 4 and 6), leading to the definition of the double-equivocal category. When we assessed HER2 gene levels in these cases by a PCR-based method we observed copy gain in 25%. When we tested HER2 protein levels by an in situ quantitative assay, HER2 levels ranged from those of score 0/ISH- to those observed in score 2+/ISH+ BCs. These data suggest that, rather than exploring alternative methods to assess HER2 status, a complementary functional approach may be beneficial. Our aim was to stratify double-equivocal BCs using global transcriptomics.
METHODS & RESULTS: We retrieved a series of 27 formalin fixed paraffin embedded double-equivocal BCs and two control groups matched for oestrogen receptor and histological grade: 22 HER2- (IHC score 0/ISH-) and 22 HER2+ (IHC score 3+/ISH+) BCs. RNA was extracted following microdissection to enrich for tumor cell content >80% and subjected to whole-Genome DASL (cDNA-mediated Annealing, Selection, extension and Ligation; Illumina).
We first identified genes with differential expression in HER2+ versus HER2- BCs based on T-test significance (p<0.01) and on mean gene expression variations higher than +/- 2-fold. To best characterize the signature we performed a cluster analysis with the GEDAS software using the "Fuzzy Self-organizing Maps" algorithm and the cosenic distance to generate the clusters. The classifier (24 genes) tested on double-equivocal cases led to a separation in "HER2+ like" and "HER2- like" BCs. More in details, three main clusters emerged, showing a significantly different distribution of cases with distinct HER2 status (p<0.0001, Chi square). Cluster A included all HER2+ and 5 double-equivocal cases and was associated to high expression of genes that pertain to the HER2 amplicon. Cluster B, composed of 9 HER2- and 12 double-equivocal cases, showed low expression of HER2 and HER2 amplicon-related genes and high levels of expression of TPRG1, NOVA1, AGTR1, SEZ6L, MAPT, GSTM1, SORCS1, DSCR6, NPY1R genes. Cluster C, formed by 13 HER2- and 10 double-equivocal cases, showed low expression of HER2 and HER2 amplicon-related genes but a non-homogeneous expression of the other genes of the classifier.
The expression of best performing genes of the classifier (TPRG1, NOVA1, AGTR1) was investigated in The Cancer Genome Atlas (TCGA) dataset of breast cancer (Breast Invasive Carcinoma, TCGA provisional from cbioportal.org) and a striking mutually exclusive pattern with HER2 expression was observed.
CONCLUSION: By resolving HER2 double-equivocal BCs into HER2 likely-positive or likely-negative, this approach may pave the way to an informed therapeutic decision in this controversial category of patients.
Citation Format: Marchio C, Trisolini E, Maletta F, Annaratone L, Scalzo MS, Mascali D, Verdun di Cantogno L, Medico E, Sapino A. Stratification of breast carcinomas with double-equivocal HER2 status. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-05-04.
Collapse
Affiliation(s)
- C Marchio
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - E Trisolini
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - F Maletta
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - L Annaratone
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - MS Scalzo
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - D Mascali
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - L Verdun di Cantogno
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - E Medico
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| | - A Sapino
- University of Turin, Turin, Italy; Pathology Unit, Azienda Ospedaliera Città Della Salute e Della Scienza di Torino, Turin, Italy; Candiolo Research Institute, University of Turin, Candiolo, Italy
| |
Collapse
|